VEGFA and cancer: Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2, which is currently used in the clinic for cancer treatment and has been approved by the Food and Drug Administration (FDA)16–19.